TABLE 1.

Hospital laboratory-reported antibiotic susceptibilities of clinical Pseudomonas aeruginosa isolates^a

Isolate	Sample site	Susceptible, standard dosing regimen	Susceptible, increased exposure	Resistant
CF02-SP01	Sputum	Ceftazidime, aztreonam, gentamicin		Amikacin, ciprofloxacin, tobramycin
CF06-SP01	Sputum	Ceftazidime, meropenem, tobramycin		Ciprofloxacin
CF07-SP03	Sputum	Meropenem, tobramycin	Ceftazidime, ciprofloxacin
CF09-SP02	Sputum	Tobramycin	Ceftazidime	Ciprofloxacin, meropenem
CF12-SP02	Sputum		Ceftazidime, piperacillin-tazobactam	Ciprofloxacin, meropenem, tobramycin
CF02-S04	Sinus	Meropenem, tobramycin	Ceftazidime	Ciprofloxacin
CF07-S01	Sinus	Ceftazidime, ciprofloxacin, meropenem, tobramycin
CF07-S05	Sinus	Meropenem, tobramycin	Ceftazidime, ciprofloxacin
CF09-S04	Sinus	Tobramycin		Ceftazidime, ciprofloxacin, meropenem
CF12-S04	Sinus			Ceftazidime, ciprofloxacin, meropenem, tobramycin

^a Each isolate name denotes patient (CF##), sample site [SP = sputum, S = sinus (middle meatal swab)], and sampling episode. Our hospital laboratory reports a “susceptible, increased exposure” result for P. aeruginosa with wild-type sensitivity to the antibiotics in this column.